[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362612-105":59,"doc-detail-362612-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-landscape-immune-microenvironment-and-survival-in-male-versus-female-breast-cancer-original-article","Genomic landscape, immune microenvironment and survival in male versus female breast cancer - Original article","","Male breast cancer accounts for about 1% of breast malignancies and differs from female breast cancer in ways that may affect prognosis and treatment response. This study characterizes the molecular and immune landscape of male breast cancer using whole-transcriptome and whole-exome sequencing data from 19,697 tumor samples. Significant sex-based differences emerge across tumor subtypes, including shifts in macrophage polarization, dendritic cell presence, checkpoint gene expression, and distinct mutation profiles with potential resistance mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-landscape-immune-microenvironment-and-survival-in-male-versus-female-breast-cancer-original-article/362612/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-landscape-immune-microenvironment-and-survival-in-male-versus-female-breast-cancer-original-article/362612.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on male versus female breast cancer?","Question",{"text":112,"@type":113},"To characterize sex-based differences in the molecular, transcriptomic, and immune landscape of male breast cancer and to identify candidate therapeutic targets and resistance mechanisms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the genomic analyses performed?",{"text":117,"@type":113},"Whole-transcriptome and whole-exome sequencing were conducted on 19,697 deidentified tumor samples provided by Caris Life Sciences.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune and molecular differences were reported between male and female breast cancer?",{"text":121,"@type":113},"Male breast cancer showed increased tumor-promoting M2 macrophages, reduced dendritic cell infiltration, and decreased immune checkpoint gene expression, alongside mutation frequency differences across molecular subtypes such as TP53 and ESR1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362612,1790333983,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ORIGINAL ARTICLE  \nGenomic landscape, immune microenvironment and survival in male versus female breast cancer✫  \nD. Trapani1 , 2 , 3 , 4, S. K. Deshmukh5, T. Samec5, S. Wu5, J. Xiu5, P. Walker5, D. L. Abravanel1 , 2 , 6, P. Advani7,  \nP. M. Spanheimer8, N. U. Lin1 , 2 , 6, G. Curigliano3 , 4, S. L. Graff9, M. Lustberg10, G. W. Sledge5, S. M. Tolaney1 , 2 , 6 &  \nJ. P. Leone1 , 2 , 6 ∗  \n1Medical Oncology, Dana-Farber Cancer Institute, Boston; 2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; 3European Institute of Oncology, IRCCS, Milan; 4University of Milano, Department of Oncology and Hematology, Milan, Italy; 5Caris Life Sciences, Phoenix; 6Harvard Medical School, Boston; 7Division of Hematology and Oncology, Mayo Clinic, Jacksonville; 8University of North Carolina, Chapel Hill; 9Brown University Health, Lifespan Cancer Institute, Legorreta Cancer Center, Providence; 10Center for Breast Cancer, Yale School of Medicine, New Haven, USA  \nAvailable online xxx  \nBackground: Male breast cancer (MaBC) represents ∼1% of breast malignancies and may have significant differences to female BC (FeBC) that impact prognosis and treatment response. In this work, we sought to characterize the molecular and immune landscape of MaBC.  \nMaterials and methods: We analyzed whole-transcriptome (WTS) and whole exome sequencing from 19 697 deidentified tumor samples provided to Caris Life Sciences.  \nResults: Our study found significant sex-based differences in the molecular and immunological landscape within each tumor subtype between MaBC and FeBC, including increased M2 Mϕ, and decreased dendritic cells and immunerelated gene expression. Genetic amplifications and mutation frequency differences between MaBC and FeBC across molecular subtypes included significant differences in TP53 and ESR1 mutation [2 .4% versus 31. 2%; 5.8% versus 13.3%, hormone receptor (HR)-positive/HER2-negative], and BRCA2 and CDH1 mutation [6 .7% versus 2. 1%, HER2-positive; 16.7% versus 5.6%, triple-negative breast cancer (TNBC)] . Immunologically, MaBC exhibited increased tumor-promoting M2 Mϕ (5 .8% versus 3.0%, TNBC), decreased dendritic cell infiltration (2 . 2% versus 2.6%, HR-positive/HER2-negative) and decreased PDCD1 and LAG3 immune checkpoint gene expression (0 .3% versus 0.4%; 2.3% versus 2.9%, HR-positive/HER2-negative) against FeBC.  \nConclusions: Our findings suggest a unique genomic and immunologic landscape in MaBC requiring a sex-informed approach and provide candidate therapeutic targets and mechanisms of resistance.  \nKey words: male breast cancer, HER2, hormone receptor, triple-negative breast cancer, molecular oncology  \nINTRODUCTION  \nBreast cancer (BC) is a leading cause of morbidity and mortality in women, but it is rare in men: out of an estimated 20 000 new BC cases diagnosed in 2020 (2650 of them in the United States) only around 1% occurred in men.1,2 Identified risk-increasing conditions for male breast cancer (MaBC) include unbalanced lifetime estrogen exposure for such conditions as hereditary gonadal dysgenesis (e.g. Klinefelter syndrome) and possibly female  \n*Correspondence to: Dr Jose P. Leone, Department of Medicine, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Tel: +617-632- 3800  \nE-mail: [josep_leone@dfci.harvard.edu](josep_leone@dfci.harvard.edu) (J. P. Leone).  \n✫Note: This study was previously presented as a Poster Spotlight Discussion (PS13-09) at the 2023 San Antonio Breast Cancer Symposium.  \n2059-7029/© 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \ngender-affirmation hormone treatments in transgender persons, family history of breast cancer, and germline cancer-predisposing mutations, mostly BRCA1 and BRCA2 .3,4 In unselected MaBC, around 10% of patients ha","cbCaidXTzlKGRMf5","https://ap.wps.com/l/cbCaidXTzlKGRMf5","pdf",3546226,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction\n# Materials and methods","[{\"question\":\"What is the main goal of this study on male versus female breast cancer?\",\"answer\":\"To characterize sex-based differences in the molecular, transcriptomic, and immune landscape of male breast cancer and to identify candidate therapeutic targets and resistance mechanisms.\"},{\"question\":\"How were the genomic analyses performed?\",\"answer\":\"Whole-transcriptome and whole-exome sequencing were conducted on 19,697 deidentified tumor samples provided by Caris Life Sciences.\"},{\"question\":\"What immune and molecular differences were reported between male and female breast cancer?\",\"answer\":\"Male breast cancer showed increased tumor-promoting M2 macrophages, reduced dendritic cell infiltration, and decreased immune checkpoint gene expression, alongside mutation frequency differences across molecular subtypes such as TP53 and ESR1.\"}]","Genomic landscape, immune microenvironment and survival in male versus female breast cancer - Original article | PDF",1790148546,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f2c44ee03e52b290004283a5ddd2693.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc87dc472b7f45c3a645c562d2593e46.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2946db91f1a8b5a4e244930fcf1cf4e3.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28ff85f8d009cad3248dd42efb5e0d6b.webp",980,1265]